CN101646435B - 6,9-二取代的嘌呤衍生物及其在皮肤治疗中的应用 - Google Patents

6,9-二取代的嘌呤衍生物及其在皮肤治疗中的应用 Download PDF

Info

Publication number
CN101646435B
CN101646435B CN200780031839XA CN200780031839A CN101646435B CN 101646435 B CN101646435 B CN 101646435B CN 200780031839X A CN200780031839X A CN 200780031839XA CN 200780031839 A CN200780031839 A CN 200780031839A CN 101646435 B CN101646435 B CN 101646435B
Authority
CN
China
Prior art keywords
skin
purine
cells
application
tetrahydropyranyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780031839XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101646435A (zh
Inventor
L·祖科瓦
M·扎鲁卡尔
L·斯皮恰
L·弗勒利希
K·多乐泽尔
M·斯特纳德
F·J·马西诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Experimental Botany Academy CAS
Original Assignee
Institute of Experimental Botany Academy CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Experimental Botany Academy CAS filed Critical Institute of Experimental Botany Academy CAS
Publication of CN101646435A publication Critical patent/CN101646435A/zh
Application granted granted Critical
Publication of CN101646435B publication Critical patent/CN101646435B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CN200780031839XA 2006-07-10 2007-07-10 6,9-二取代的嘌呤衍生物及其在皮肤治疗中的应用 Expired - Fee Related CN101646435B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80687106P 2006-07-10 2006-07-10
US60/806,871 2006-07-10
US11/774,652 US20080009508A1 (en) 2006-07-10 2007-07-09 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
US11/774,652 2007-07-09
PCT/US2007/073142 WO2008008770A2 (en) 2006-07-10 2007-07-10 6, 9-disubstituted purine derivatives and their use for treating skin

Publications (2)

Publication Number Publication Date
CN101646435A CN101646435A (zh) 2010-02-10
CN101646435B true CN101646435B (zh) 2012-08-22

Family

ID=38919793

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780031839XA Expired - Fee Related CN101646435B (zh) 2006-07-10 2007-07-10 6,9-二取代的嘌呤衍生物及其在皮肤治疗中的应用

Country Status (16)

Country Link
US (4) US20080009508A1 (OSRAM)
EP (1) EP2043630B1 (OSRAM)
JP (1) JP5309023B2 (OSRAM)
KR (1) KR101478727B1 (OSRAM)
CN (1) CN101646435B (OSRAM)
AU (1) AU2007272576B2 (OSRAM)
BR (1) BRPI0714161A2 (OSRAM)
CA (1) CA2657516C (OSRAM)
EA (1) EA015848B1 (OSRAM)
ES (1) ES2603216T3 (OSRAM)
IL (1) IL196442A (OSRAM)
MX (1) MX2009000347A (OSRAM)
MY (1) MY158100A (OSRAM)
NO (1) NO20090598L (OSRAM)
NZ (1) NZ574711A (OSRAM)
WO (1) WO2008008770A2 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960397B2 (en) * 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9096852B2 (en) 2010-06-09 2015-08-04 Chanel Parfums Beaute Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
EP2395086A1 (en) * 2010-06-09 2011-12-14 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PL3513793T3 (pl) 2011-09-02 2021-09-20 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
US20130072506A1 (en) 2011-09-16 2013-03-21 Lenka ZAHAJSKA 6,8-disubstituted purine compositions
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CZ306984B6 (cs) * 2014-12-15 2017-11-01 Ústav experimentální botaniky AV ČR, v. v. i. 6,8-Disubstituované-9-(heterocyklyl)puriny, přípravky obsahující tyto deriváty a jejich použití v kosmetických a medicínských aplikacích
RS63963B1 (sr) 2015-02-27 2023-03-31 Incyte Holdings Corp Postupak pripreme pi3k inhibitora
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CZ307722B6 (cs) * 2015-08-28 2019-03-27 Univerzita PalackĂ©ho v Olomouci Adeninové deriváty a jejich použití
CZ307868B6 (cs) * 2017-04-28 2019-07-10 Univerzita PalackĂ©ho v Olomouci Deriváty 9-(2-oxacykloalkyl)-9H-purin-2,6-diaminu, přípravky obsahující tyto deriváty a jejich použití
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
EP4178959B1 (en) 2020-07-13 2025-09-10 Univerzita Palackého v Olomouci Nitrogen heterocyclic cytokinin derivatives, compositions containing these derivatives and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602139A (en) * 1987-02-26 1997-02-11 Senetek Plc Method for ameliorating the adverse effects of aging
US20050113340A1 (en) * 2003-09-18 2005-05-26 Conforma Therapeutics Corporation 2-Aminopurine analogs having HSP90-inhibiting activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021422A (en) * 1989-06-08 1991-06-04 Senetek Plc Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
AU2003274652A1 (en) * 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
EP1901817A2 (en) * 2005-07-08 2008-03-26 The Procter and Gamble Company Personal care compositions and methods for the beautification of mammalian skin and hair

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602139A (en) * 1987-02-26 1997-02-11 Senetek Plc Method for ameliorating the adverse effects of aging
US20050113340A1 (en) * 2003-09-18 2005-05-26 Conforma Therapeutics Corporation 2-Aminopurine analogs having HSP90-inhibiting activity

Also Published As

Publication number Publication date
IL196442A0 (en) 2009-11-18
EP2043630A4 (en) 2010-12-29
WO2008008770A2 (en) 2008-01-17
CN101646435A (zh) 2010-02-10
ES2603216T3 (es) 2017-02-24
CA2657516C (en) 2016-05-10
MX2009000347A (es) 2009-03-20
US20080009508A1 (en) 2008-01-10
KR101478727B1 (ko) 2015-01-02
BRPI0714161A2 (pt) 2012-12-25
CA2657516A1 (en) 2008-01-17
US20100234401A1 (en) 2010-09-16
AU2007272576B2 (en) 2012-05-17
MY158100A (en) 2016-08-30
EP2043630B1 (en) 2016-09-07
IL196442A (en) 2015-10-29
NO20090598L (no) 2009-04-14
US20130072505A1 (en) 2013-03-21
WO2008008770A3 (en) 2008-04-10
EA015848B1 (ru) 2011-12-30
EA200970110A1 (ru) 2009-06-30
NZ574711A (en) 2012-05-25
KR20090047457A (ko) 2009-05-12
EP2043630A2 (en) 2009-04-08
AU2007272576A1 (en) 2008-01-17
JP5309023B2 (ja) 2013-10-09
US20110224238A1 (en) 2011-09-15
JP2009543799A (ja) 2009-12-10

Similar Documents

Publication Publication Date Title
CN101646435B (zh) 6,9-二取代的嘌呤衍生物及其在皮肤治疗中的应用
US5371089A (en) Method and composition for ameliorating the adverse effects of aging
BRPI0609630A2 (pt) composições e métodos para tratamento de doenças epidérmicas hiperproliferativas
KR20020069482A (ko) 레티노이드 피부 손상의 억제 방법
JP2021510159A (ja) セルドゥラチニブ含有局所皮膚医薬組成物およびその使用
US20060204471A1 (en) Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging
KR102039302B1 (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도
KR101792402B1 (ko) 니코틴산 아데닌 디뉴클레오티드 인산 및 그 유도체를 포함하는 발모 또는 육모 촉진제
JP5179352B2 (ja) ウイルス性障害の治療のためのカルコン類の使用
CN117297999A (zh) 一种改善皮肤状态的组合物及其应用
HK1140425A (en) 6,9-disubstituted purine derivatives and their use for treating skin
KR102751617B1 (ko) 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물
CN117205106B (zh) 一种多重乳化的保湿修复霜及其制备方法
JP2001508789A (ja) 皮膚の生態と適合性の化粧料用又は皮膚医薬用製品
CN119970543A (zh) 酒渣碱的美容应用
CN117731672A (zh) 一种促毛发生长的制剂及其制备方法和应用
JP2024081301A (ja) 皮膚幹細胞の増殖促進剤
JP2024061100A (ja) 皮膚幹細胞の増殖促進剤
KR20210070777A (ko) 피부장벽 강화용 조성물
CN110115697A (zh) 含冬虫夏草的防治皮肤炎症的组合物
KR20160137035A (ko) 아토피 피부염증 치료용 식물추출 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Inventor

Correct: Szucova Lucie|Zatloukal Marek|Spichal Lukas|Frohlich Ludek|Dolezal Karel|M Si Tenade|Massino Frank J.

False: Szucova Lucie|Zatloukal Marek|Spichal Lukas|Frohlich Ludek|Dolezal Karel|M Si Tenade|Massino Frank J.

Number: 06

Volume: 26

CI02 Correction of invention patent application

Correction item: Inventor

Correct: Dolezal Karel

False: Dolezal Karel

Number: 06

Page: The title page

Volume: 26

ERR Gazette correction

Free format text: CORRECT: INVENTOR; FROM: L SZUCOVA M ZATLOUKAL L SPICHAL L FROHLICH J DOLEZAL M STRNAD F J MASSINO TO: L SZUCOVA M ZATLOUKAL L SPICHAL L FROHLICH K DOLEZAL M STRNAD F J MASSINO

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1140425

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1140425

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

Termination date: 20210710

CF01 Termination of patent right due to non-payment of annual fee